No change of treatment for giant cell arteritis

Adding a newer drug to standard corticosteroid treatment of giant cell arteritis does not help to reduce the dose of corticosteroids needed. INTRODUCTION Giant cell arteritis is a condition where the large blood vessels of the head and neck become inflamed. It can cause soreness around the temples, pain in the jaw while eating, and (if untreated) […]

Read More…

Newly updated advice on using DMARDs for RA

INTRODUCTION Shared decision-making between patients and doctors is a central focus of newly updated recommendations on treating rheumatoid arthritis with disease-modifying antirheumatic drugs (DMARDs). The updated recommendations, produced by the European League Against Rheumatism (EULAR), also take into account recent research on the benefits and safety of these widely used drugs. WHAT DO WE KNOW ALREADY? When […]

Read More…

Benefits of anti-TNF for psoriatic arthritis prompts early treatment questions

Medicines called anti-TNF drugs can help stop the joint damage caused by psoriatic arthritis from getting worse, according to new research. Doctors think that if people take these medicines soon enough after they are told they have psoriatic arthritis, it could help prevent damage to joints. WHAT DO WE KNOW ALREADY? Psoriatic arthritis is a […]

Read More…

New treatment targets for ankylosing spondylitis and psoriatic arthritis

INTRODUCTION A treatment approach based on clear targets for individual patients has helped relieve symptoms and improve quality of life for many people with rheumatoid arthritis. Now a report explains how the same approach could help people with other rheumatic conditions. WHAT DO WE KNOW ALREADY? Using clear treatment targets can help doctors and patients […]

Read More…

Why anti-TNF treatments don’t work the same for everyone

  INTRODUCTION Some people who take treatments called anti-TNF drugs for illnesses like rheumatoid arthritis, psoriasis and spondyloarthritides may get less benefit than other people who take the same treatments, because their immune systems stop the drugs working properly. WHAT DO WE KNOW ALREADY? Anti-TNF drugs are used to reduce inflammation (for example joint swelling). […]

Read More…

Promising early results for new rheumatoid arthritis treatment

INTRODUCTION An early trial of a new drug called mavrilimumab suggests that it may become a useful new treatment for people with moderate to severe rheumatoid arthritis. WHAT DO WE KNOW ALREADY? Despite big steps forward in the treatment of rheumatoid arthritis in recent years, there are still many people who don’t benefit much from the available […]

Read More…

Potential treatment for lupus nephritis without oral steroids

INTRODUCTION A small study of a new combination treatment for lupus nephritis that doesn’t include oral steroids has shown encouraging results. If larger studies show similar results, the new combination treatment could help people with this condition avoid the side effects of long-term treatment with high doses of oral steroids. WHAT DO WE KNOW ALREADY? Lupus nephritis […]

Read More…

Do better treatments mean fewer appointments for rheumatoid arthritis?

INTRODUCTION Twenty-first-century treatments may be behind a drop in hospital and doctor visits for people with rheumatoid arthritis, according to a study in Sweden. WHAT DO WE KNOW ALREADY? In the first part of this century, a number of medicines have made a big difference to people living with the symptoms of rheumatoid arthritis, such as pain, […]

Read More…

Do patients prefer nurse specialists to manage their DMARD treatment?

INTRODUCTION People taking disease-modifying antirheumatic drugs (DMARDs) for inflammatory arthritis are more likely to be satisfied with their care if they have follow-up appointments with a clinical nurse specialist, rather than with a doctor, a study shows. WHAT DO WE KNOW ALREADY? ‘Inflammatory arthritis’ is an umbrella term that covers several conditions, including rheumatoid arthritis, ankylosing spondylitis, […]

Read More…